Plasma Zinc Difference in Children with Thalassemia β Major Received Deferiprone or Deferasirox Zinc
Abstract
Background: Thalassemia is a blood disease characterized by the most frequently found autosomal recessive hereditary hemolytic anemia. It requires repeated blood transfusions for life. Routine blood transfusion can cause complications in the form of accumulation of ferritin in the tissue. Iron chelation therapy is considered effective for treating body iron deposits. However, iron chelation therapy has the side effect of decreasing levels of other important minerals such as zinc (Zn). This study aimed to examine plasma zinc difference in children with Thalassemia β major received deferiprone or deferasirox zinc.
Subjects and Method: This was a cross sectional study conducted at Dr. Moewardi Hospital, Surakarta, from February to April 2017. A sample of 40 children with thalassemia β major aged 3 to 18 years who received deferiprone iron chelation and deferasirox at least 6 months was selected by consecutive sampling. The dependent variable was serum zinc levels. The independent variables were iron deferiprone and deferasirox. Plasma zinc levels were measured by atomic absorption spectroscope. The data were analyzed by t test.
Results: Zinc levels in patients with deferiprone therapy (Mean= 54.50; SD= 11.02) were lower than deferasirox therapy (Mean= 60.95; SD= 20.71), but statistically not significant (p= 0.229).
Conclusion:Zinc levels in patients with deferiprone therapy are lower than deferasirox therapy, but not statistically significant.
Keywords: zinc, deferiprone, deferasirox, children with thalassemia β major
Correspondence: Wahyu Kusumawardhani. Department of Pediatrics, Faculty of Medicine, Universitas Sebelas Maret/ Dr. Moewardi Hospital, Surakarta, Central Java. Phone/ Fax: 0271-633348. Email: dhanisuryadiraja@gmail.com
Indonesian Journal of Medicine (2020), 05(02): 102-108
https://doi.org/10.26911/theijmed.2020.05.02.02
References
Hagag AA, Elfaragy MS, Elrifaey SM, Abd ElLateef AE (2015). Therapeutic value of combined therapy with deferiprone and silymarinas iron chelators in Egyptian children with beta thalassemia major. Infect Disord Drug Targets, 15(3): 189 – 195. https://doi.org/10.2174/1871526515666150731113305
Al-Kloub MI, A Bed MA, Al Khawaldeh OA, Al Tawarah YM, Froelicher ES (2014). Predictors of non-adherence to followup visits and deferasirox chelation therapy among Jordanian adolescents with thalassemia major. Pediatr Hematol Oncol, 31(7): 624–637. https://doi.org/10.3109/08880018.2014.939792
Chuansumrit A, Pengpis P, Mahachoklertwattana P, Sirachainan N, Poomthavorn P, Sungkarat W, Kadegasem P, Khlairit P, Wongwerawattanakoon P (2016). Effect of iron chelation therapy on glucose metabolism in non-transfusion dependent thalassaemia. Acta Haematol, 137(1): 20–26. https://doi.org/10.1159/000450673
Fung EB (2016). The importance of nutrition for health in patients with transfusiondependent thalassemia. Ann Ny Acad Sci, 1368(1): 40–48. https://doi.org/10.1111/nyas.13003
Gomber S, Dabas A, Bagmar S, Madhu SV (2017). Glucose homeostasis and effect of chelation on β cell function in children with β-Thalassemia major. J Pediatr Hematol Oncol. 40(1):56-59. https://doi.org/10.1097/MPH.0000000000001043
Jensen PD (2002). Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias. Bld, 101(1): 91–96. https://doi.org/10.1182/blood-2002-06-1704
Kizilgun M, Takci S, Erkekoglu P, Asci A, Balci A, Yigit S, Kocer-Gumusel B (2016). Copper, zinc and iron levels in premature infants following red blood cell transfusion. J Trace Elem Med Bio, 38: 126–130. https://doi.org/10.1016/j.jtemb.2016.05.011
Kulathinal S, Freese R, Korkalo L, Ismael C, Mutanen M (2016). Mid-upper arm circumference is associated with biochemically determined nutritional status indicators among adolescent girls in Central Mozambique. Nutr Res Rev, 36(8): 835–844. https://doi.org/10.1016/j.nutres.2016.04.007
LachowiczJI, NurchiVM, Crisponi G, Jaraquemada-Pelaez MG, Ostrowska M, Jezierska J, Gumienna-Kontecka E, et al. (2015). Zinc(II) and copper(II) complexes with hydroxypyrone iron chelators. J Inorg Biochem, 151: 94–106. https://doi.org/10.1016/j.jinorgbio.2015.08.011
Vosper J, Evangeli M, Porter JB, Shah F (2018). Psychological Factors Associated with Episodic Chelation Adherence in Thalassemia. Hb, 42(1): 30–36. https://doi.org/10.1080/03630269.20-18.1433686
Zekavat OR, Bahmanjahromi A, Haghpanah S, Ebrahimi S, Cohan N (2018). The Zinc and Copper Levels in Thalassemia Major Patients, Receiving Iron Chelation Therapy. J Pediatr Hematol Oncol. 40(3): 178–181. https://doi.org/10.1097/mph.0000000000001102
